Related Experiment Video
Updated: Jun 13, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
Published on: September 26, 2013
Interferon-beta inhibits Th17 cell differentiation in patients with multiple sclerosis
Vinod S Ramgolam1, Silva Markovic-Plese
1Department of Neurology, University of North Carolina at Chapel Hill, USA.
Interferon-beta (IFNbeta) has been used over the past 15 years as a first-line therapy for relapsing remitting multiple sclerosis (RR MS), however its mechanisms of action are still not completely elucidated. Recently discovered Th17 cells have been hypothesized to play a crucial role in the development of autoimmune diseases, including MS. Studies from our laboratory and others have demonstrated that IFNbeta treatment suppresses Th17 cells' differentiation, mediated by its effects on dendritic cells (DCs), B-cells and T-cells. IFNbeta induces the production of the Th17-suppressive cytokines interleukin (IL)-27 and IL-12 in DCs and B-cells through the phosphorylation of signal transducers and activators of the transcription protein (STAT)1. Its inhibition of the Th17-promoting cytokines IL-1b and IL-23 is mediated via induction of suppressor of cytokine signaling (SOCS)3 expression. In naïve CD45RA+ T-cells, IFNbeta directly suppresses Th17 cells' differentiation, as evidenced by the suppression of this cell subset's specific transcription factor retinoic acid-related orphan receptor (ROR)c, cytokine IL-17A and the surface markers chemokine receptor (CCR)6 and IL-23R. The IFNbeta-mediated induction of IL-10 in T-cells and B-cells represents an important additional immunoregulatory mechanism. Described IFNbeta's mechanisms of action selectively target Th17 cell-mediated autoimmune responses in patients with RR MS.
Interferon-beta (IFNbeta) has been used over the past 15 years as a first-line therapy for relapsing remitting multiple sclerosis (RR MS), however its mechanisms of action are still not completely elucidated. Recently discovered Th17 cells have been hypothesized to play a crucial role in the development of autoimmune diseases, including MS. Studies from our laboratory and others have demonstrated that IFNbeta treatment suppresses Th17 cells' differentiation, mediated by its effects on dendritic cells (DCs), B-cells and T-cells. IFNbeta induces the production of the Th17-suppressive cytokines interleukin (IL)-27 and IL-12 in DCs and B-cells through the phosphorylation of signal transducers and activators of the transcription protein (STAT)1. Its inhibition of the Th17-promoting cytokines IL-1b and IL-23 is mediated via induction of suppressor of cytokine signaling (SOCS)3 expression. In naïve CD45RA+ T-cells, IFNbeta directly suppresses Th17 cells' differentiation, as evidenced by the suppression of this cell subset's specific transcription factor retinoic acid-related orphan receptor (ROR)c, cytokine IL-17A and the surface markers chemokine receptor (CCR)6 and IL-23R. The IFNbeta-mediated induction of IL-10 in T-cells and B-cells represents an important additional immunoregulatory mechanism. Described IFNbeta's mechanisms of action selectively target Th17 cell-mediated autoimmune responses in patients with RR MS.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inhibitors of Viral Protein Synthesis
Multiple Sclerosis l: Introduction

